Home/Filings/8-K/0001753926-26-000194
8-K//Current report

Vivani Medical, Inc. 8-K

Accession 0001753926-26-000194

$VANICIK 0001266806operating

Filed

Jan 26, 7:00 PM ET

Accepted

Jan 27, 4:11 PM ET

Size

1.4 MB

Accession

0001753926-26-000194

Research Summary

AI-generated summary of this filing

Updated

Vivani Medical Announces $4.5M Equity Offerings

What Happened

  • Vivani Medical, Inc. (VANI) filed an 8-K (Jan 27, 2026) announcing two equity financings entered into on January 25, 2026: a private placement and a registered direct offering to raise approximately $4.5 million in gross proceeds.
  • The private placement: a Share Purchase Agreement with an entity affiliated with Gregg Williams (Chairman) to buy 1,351,351 shares at $1.48 per share (last reported sale price on Jan 23, 2026), raising about $2.0 million. No warrants or discounts were issued and no placement agent fees were paid for this private sale. The shares are being issued under Rule 506 of Regulation D.
  • The registered offering: a Placement Agency Agreement with ThinkEquity LLC to sell 1,689,200 shares in a registered direct offering, expected to raise about $2.5 million before placement agent fees and expenses. The Company agreed to pay the agent a 7.0% cash fee and reimburse up to $125,000 of the agent’s expenses. Directors and officers entered into 60‑day lock-up agreements following the offering’s closing.
  • The filing includes a legal opinion from Goodwin Procter LLP and a press release dated January 25, 2026 (filed as Exhibit 99.1).

Key Details

  • Private placement: 1,351,351 shares at $1.48/share → ≈ $2.0M gross proceeds.
  • Registered offering: 1,689,200 shares → ≈ $2.5M gross proceeds (before fees).
  • Placement agent fees for the registered offering: 7.0% of proceeds + up to $125,000 reimbursable expenses.
  • Lock-up: Company directors and officers agreed to a 60‑day post-closing lock-up for their securities.

Why It Matters

  • The combined financings provide Vivani approximately $4.5M in fresh capital, which can help fund operations, development, or other corporate needs. However, issuing new shares will dilute existing shareholders’ ownership.
  • The registered offering’s 7% fee and reimbursable expenses will reduce net proceeds. The private placement involved an affiliate of the chairman, which signals insider participation but also is an insider-related transaction that investors should note.
  • The 60‑day lock-up limits immediate insider selling after the registered offering closes, which can help near-term market stability. Investors should monitor subsequent SEC filings for the actual closing, final net proceeds, and any updates on use of proceeds.